Triazavirin
- Generic Name
- Triazavirin
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N6O3S
- CAS Number
- 123606-06-4
- Unique Ingredient Identifier
- F2HTG1MH2D
- Background
Triazavirin is a guanine nucleotide analog antiviral originally developed in Russia that has shown efficacy against influenza A and B, including the H5N1 strain. It appears that Triazavirin has shown promise in reducing influenza disease severity and associated complications. Given the similarities between SARS-CoV-2 and H5N1, health officials are investigating Triazavirin as an option to combat SARS-CoV-2, the coronavirus responsible for COVID-19.
- Indication
Triazavirin was developed in Russia as a potential treatment of Influenza A and B infections.
Evaluation of The Efficacy of Triazavirin Versus Oseltamivir in Egyptian Patients Infected With COVID-19
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 80
- Registration Number
- NCT04973462
- Locations
- 🇪🇬
Fever Hospital of the Egyptian Armed Forces, Cairo, Egypt
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Wits Health Consortium (Pty) Ltd
- Target Recruit Count
- 74
- Registration Number
- NCT04581915
- Locations
- 🇿🇦
The Perinatal HIV Research Unit - Matlosana, Klerksdorp, North West Province, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.